Merck Has Good Reason to Buy a Cancer-Drug Biotech
by Lisa Jarvis, 8/2/22
Membership required
Membership is now required to use this feature. To learn more:
View Membership BenefitsEmail Article Recommendation
Sponsored Content
Upcoming Virtual Events View All
June 04, 2026 at
02:00 PM EDT
Accessing MLPs Through an Exchange-Traded Note
June 08, 2026 at
02:00 PM EDT
- 1.0 CE credit
Rethinking Tax-Efficient Income Generation
June 09, 2026 at
12:30 PM EDT
Why Now is the REIT Moment
June 11, 2026 at
12:30 PM EDT
Activating fixed income portfolios
June 12, 2026 at
02:00 PM EDT
- 1.0 CE credit
Variable annuities, income riders, and retirement income innovations
June 15, 2026 at
12:30 PM EDT
BCSM: Where Small-Cap Upside Meets Large-Cap Stability in an Active ETF
June 22, 2026 at
02:00 PM EDT
- 1.0 CE credit
Bitcoin, Bitcoin Mining, and Digital Power
June 23, 2026 at
02:00 PM EDT
- 1.0 CE credit
When Markets Diverge: Finding Opportunity with Free Cash Flow
June 25, 2026 at
11:00 AM EDT
- 2.0 CE credits
2026 Midyear Market Outlook Symposium
June 26, 2026 at
02:00 PM EDT
- 1.0 CE credit
The Quiet Boom in Autocallable ETFs
June 29, 2026 at
02:00 PM EDT
- 1.0 CE credit
The S&P 500 Buyback Aristocrats: Quality Through Consistency
June 30, 2026 at
02:00 PM EDT
- 1.0 CE credit
Why Munis Matter in 2026
July 16, 2026 at
11:00 AM EDT
- 1.0 CE credit
The Robot in the Room: Physical AI, Humanoids, and the Careers Your Clients' Kids Will Actually Have
August 11, 2026 at
04:00 PM EDT
- 1.0 CE credit
Automating America: The New Wave of Robotics Demand
August 31, 2026 at
12:30 PM EDT
The importance of hedging foreign currency exposure in your equity portfolio
November 12, 2026 at
11:00 AM EST
- 1.0 CE credit
2027 Market Outlook Symposium
